The estimated Net Worth of Katherine S Zanotti is at least $10.7 Millón dollars as of 8 June 2023. Ms. Zanotti owns over 3,027 units of Exact Sciences stock worth over $4,144,011 and over the last 18 years she sold EXAS stock worth over $6,243,028. In addition, she makes $326,023 as Independent Director at Exact Sciences.
Sign up
Ms. Zanotti EXAS stock SEC Form 4 insiders trading
Katherine has made over 17 trades of the Exact Sciences stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 3,027 units of EXAS stock worth $273,974 on 8 June 2023.
The largest trade she's ever made was selling 25,000 units of Exact Sciences stock on 28 February 2019 worth over $2,320,250. On average, Katherine trades about 1,900 units every 45 days since 2006. As of 8 June 2023 she still owns at least 64,629 units of Exact Sciences stock.
You can see the complete history of Ms. Zanotti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Katherine Zanotti biography
Katherine S. Zanotti serves as Independent Director of the Company. She has served as a director since April 2009. She served as chief executive officer of Arbonne International from August 2009 until June 2018. Ms. Zanotti also served as Chair of Natural Products Group (the holding company of Arbonne, Nature's Gate, and Levlad) from March 2010 until March 2018 when Groupe Rocher acquired Arbonne International. Arbonne is a botanically based skin care, cosmetic and nutrition company marketed in seven countries, with revenue of over $550 million. From July 2002 to March 2006, she served as senior vice president of marketing at McDonald's Corporation. Ms. Zanotti is a retired vice president of the Procter & Gamble Company and most recently served as vice president and general manager of the North American pharmaceutical business and the corporate women's health platform. Ms. Zanotti currently serves on the Board of Trustees of Xavier University. Ms. Zanotti currently serves as a director of Cutera, Inc., a developer of cosmetic and aesthetic laser equipment (Nasdaq:CUTR). She previously served as a director of Hill-Rom Holdings, Inc., a worldwide manufacturer and provider of medical technologies and related services (NYSE:HRC); Mentor Corporation, a medical device company; Alberto Culver Company, a personal care products company; and Third Wave Technologies, Inc., a molecular diagnostics company. Ms. Zanotti earned a bachelor's degree in economics and studio fine arts from Georgetown University and an MBA with a concentration in marketing and finance from Xavier University.
What is the salary of Katherine Zanotti?
As the Independent Director of Exact Sciences, the total compensation of Katherine Zanotti at Exact Sciences is $326,023. There are 21 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.
How old is Katherine Zanotti?
Katherine Zanotti is 65, she's been the Independent Director of Exact Sciences since 2009. There are 4 older and 19 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
What's Katherine Zanotti's mailing address?
Katherine's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON, WI, 53719.
Insiders trading at Exact Sciences
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania y Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
What does Exact Sciences do?
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
What does Exact Sciences's logo look like?
Complete history of Ms. Zanotti stock trades at Cutera Inc, Exact Sciences, Hill-Rom Inc, Virtus Diversified Income & Convertible Fund y Diversey
Exact Sciences executives and stock owners
Exact Sciences executives and other stock owners filed with the SEC include:
-
Kevin Conroy,
Chairman of the Board, President, Chief Executive Officer -
Mark Stenhouse,
General Manager - Screening -
Jeffrey Elliott,
Chief Financial Officer -
D. Scott Coward,
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary -
Jake Orville,
General Manager - Pipeline -
Ana Hooker,
Senior Vice President, Operations -
Graham Lidgard,
Senior Vice President, Chief Scientific Officer -
Kevin T. Conroy,
Chairman, Pres & CEO -
G. Bradley Cole,
Gen. Mang. of Precision Oncology -
Mark Stenhouse,
Advisor -
Graham P. Lidgard,
Emeritus Chief Science Officer -
Jeffrey T. Elliott CFA,
Exec. VP, CFO & COO -
D. Scott Coward,
Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec. -
Kathleen Sebelius,
Independent Director -
Andrew Slavitt,
Director -
Pierre Jacquet,
Independent Director -
Jake Orville,
Gen. Mang. of Pipeline -
Ana Hooker,
Sr. VP of Operations -
James Doyle,
Independent Director -
Michael Wyzga,
Independent Director -
Daniel Levangie,
Independent Director -
Katherine Zanotti,
Independent Director -
Thomas Carey,
Independent Director -
Shacey Petrovic,
Director -
Gisela Paulsen,
General Manager - Precision Oncology -
Torsten Hoof,
General Manager - International -
Freda Lewis-Hall,
Independent Director -
Scott Johnson,
Senior Vice President, Research and Development -
Vic Parker,
Head of Sales -
Tim Caprez,
Chief Compliance Counsel & VP -
Megan Jones,
Associate Mang. of Investor Relations -
Dr. Scott C. Johnson Ph.D.,
Chief Science Officer and Sr. VP of R&D -
Gary Frings,
Chief Information Officer -
Lionel Sterling,
Director -
John A. Fallon,
Director -
David Thompson,
Director -
G Bradley Cole,
General Manager - Diagnostics -
Paul J Clancy,
-
Michael J Barber,
-
Eli Casdin,
Director -
Anthony P Shuber,
Executive Vice President -
John A Jr Mccarthy,
Chief Financial Officer -
Don M Hardison,
President, CEO and Director -
Barry M Berger,
SVP, Chief Medical Officer -
William J. Megan,
SVP, Finance & PFO -
John K Bakewell,
Chief Financial Officer -
Jeffrey R Luber,
General Counsel -
Edwin M Jr Kania,
Director -
Charles R Jr Carelli,
Prin. Acct. Off. & Corp. Ctlr. -
Patrick J Zenner,
Director -
Stanley N Lapidus,
Director -
John M Krayacich,
SVP, Sales and Marketing -
Richard W Barker,
Director -
Laura S Stoltenberg,
Chief Commercial Officer -
Cornelius Iii Mcgillicudy,
Director -
Harry W Wilcox,
Senior Vice President and CFO -
Lance Willsey,
Director -
Michael E Singer,
Director -
Maneesh Arora,
Vice President -
James P Connelly,
Director -
Sally Crawford,
Director -
Sarah Condella,
EVP, Human Resources -
Timothy J Scannell,
Director -
James Herriott,
SVP, General Counsel & Sec -
Everett Cunningham,
Chief Commercial Officer -
Jacob A Orville,
EVP, GM, Screening -
Brian Baranick,
EVP, GM, Precision Oncology